X0508 4 2025-06-02 0001088856 CORCEPT THERAPEUTICS INC CORT 0001698310 Maduck Sean C/O CORCEPT THERAPEUTICS INCORPORATED 101 REDWOOD SHORES PARKWAY REDWOOD CITY CA 94065 false true false false See Remarks true Common Stock 2025-06-02 4 A false 888 71.68 A 16817 D Common Stock 2025-06-02 4 A false 888 0 A 17705 D Common Stock 2025-06-02 4 A false 20000 5.05 A 37705 D Common Stock 2025-06-02 4 S false 5752 77.9101 D 31953 D Common Stock 2025-06-02 4 S false 6191 78.8744 D 25762 D Common Stock 2025-06-02 4 S false 6246 79.8859 D 19516 D Common Stock 2025-06-02 4 S false 1811 80.7669 D 17705 D Common Stock 89693 I See Footnote Common Stock 10000 I See Footnote Stock option (right to buy) 5.05 2025-06-02 4 M false 20000 0 D 2026-05-02 Common Stock 20000 61986 D The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 2, 2025. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $77.56 to $78.515 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $78.57 to $79.5675 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.5725 to $80.535 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $80.585 to $81.00 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Fully exercisable. President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission. /s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck 2025-06-04